ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
Harnessing the synergy of contact brachytherapy and immune checkpoint inhibitors in advanced melanoma: first reported case series.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The optimal approach to the primary treatment of uveal melanoma: a narrative review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melanoma is an aggressive malignancy with high metastatic potential, often requiring systemic treatment with immune checkpoint inhibitors (CHI) in advanced stages. While CHI has significantly improved outcomes, its combination with local radiotherapy - particularly brachytherapy (BT) - may further enhance therapeutic efficacy by promoting immunogenic tumor cell death. BT enables precise delivery of high radiation doses, providing rapid symptom relief and potentially triggering local and systemic immune responses. This case series presents the first known clinical experience with noninvasive contact high-dose-rate brachytherapy (HDR-BT) combined with CHI in patients with metastatic melanoma treated in a palliative setting. Materials and methods: We retrospectively analyzed four patients with stage IV melanoma and symptomatic subcutaneous metastases, all receiving ongoing CHI (nivolumab or pembrolizumab). Each underwent a single HDR-BT session (5-7 Gy) using a Freiburg Flap applicator. The primary goal was symptom relief. Treatment response was assessed clinically and radiologically, focusing on local control, response of non-irradiated lesions, progression-free survival (PFS), and overall survival (OS). Results: All patients experienced rapid clinical improvement and significant regression of the irradiated lesion, with minimal (Grade 0-1) acute skin toxicity. In two cases, complete remission of treated sites was achieved. One patient demonstrated long-term remission in both subcutaneous and visceral metastases. Median PFS was 3.4 months (range: 1.5-15.0), and OS ranged from 8.5 to 22 months. Conclusions: Single-fraction contact HDR-BT in combination with CHI appears to be a safe and effective palliative strategy for metastatic melanoma, offering fast local control, minimal toxicity, and potential systemic immune benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.